Aileron Therapeutics Files 8-K on Shareholder Nominations
Ticker: RNTX · Form: 8-K · Filed: Jun 5, 2024 · CIK: 1420565
| Field | Detail |
|---|---|
| Company | Aileron Therapeutics, Inc. (RNTX) |
| Form Type | 8-K |
| Filed Date | Jun 5, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, shareholder-activism
TL;DR
Aileron Therapeutics filed an 8-K about shareholder nominations - could be board shakeup incoming.
AI Summary
Aileron Therapeutics, Inc. filed an 8-K on June 5, 2024, to report on shareholder nominations pursuant to Exchange Act Rule 14a-11 and other events. The filing does not contain specific financial figures or details about the nature of the shareholder nominations or other events.
Why It Matters
This filing indicates potential changes or activism related to Aileron Therapeutics' board or strategic direction, which could impact its future operations and stock performance.
Risk Assessment
Risk Level: medium — The filing suggests potential corporate governance changes or shareholder activism, which can introduce uncertainty and volatility.
Key Players & Entities
- Aileron Therapeutics, Inc. (company) — Registrant
- Exchange Act Rule 14a-11 (regulation) — Subject of filing
FAQ
What is the specific nature of the shareholder nominations being reported?
The filing does not provide specific details regarding the nature or identity of the shareholder nominations.
What are the 'other events' mentioned in the filing?
The filing does not elaborate on the specific 'other events' that are being reported.
When was this 8-K filing submitted?
The filing was submitted on June 5, 2024.
What is Aileron Therapeutics, Inc.'s principal executive office address?
The principal executive offices are located at 12407 N. Mopac Expy., Suite 250 #390, Austin, Texas 78758.
What is the company's telephone number?
The company's telephone number is (737) 802-1989.
Filing Stats: 723 words · 3 min read · ~2 pages · Grade level 11.2 · Accepted 2024-06-05 06:58:30
Key Financial Figures
- $0.001 — ange on which registered Common Stock, $0.001 par value per share ALRN The Nasdaq
Filing Documents
- d839689d8k.htm (8-K) — 26KB
- 0001193125-24-154675.txt ( ) — 148KB
- alrn-20240605.xsd (EX-101.SCH) — 3KB
- alrn-20240605_lab.xml (EX-101.LAB) — 18KB
- alrn-20240605_pre.xml (EX-101.PRE) — 11KB
- d839689d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AILERON THERAPEUTICS, INC. Date: June 5, 2024 By: /s/ Brian Windsor Brian Windsor, Ph.D. President and Chief Executive Officer